Exploring the Potential Drug Target TBC1D29P: A putative TBC1 Domain Family Member 29

Target Name: TBC1D29P

NCBI ID: G26083

TBC1D29P

Exploring the Potential Drug Target TBC1D29P: A putative TBC1 Domain Family Member 29

Introduction

The protein TBC1D29P (TBC1 domain family member 29) has been identified as a potential drug target and biomarker in various diseases, including cancer. This protein plays a crucial role in the regulation of cell growth, apoptosis, and angiogenesis, which are critical processes in the development and progression of many diseases. Therefore, the development of compounds that can specifically target TBC1D29P and modulate its function could lead to new therapeutic approaches for various diseases.

Structure and Function

TBC1D29P is a member of the TBC1 domain family, which is characterized by the presence of a unique N-terminal region that contains a putative transmembrane domain and a N-terminal cytoplasmic domain. The TBC1 domain is involved in various cellular processes, including cell adhesion, migration, and invasion.

TBC1D29P is a 29kDa protein that contains 216 amino acid residues. The protein has a unique N-terminal region that is hinge-shaped and contains a putative transmembrane domain. The transmembrane domain is made up of a variable number of transmembrane domains, which are involved in the regulation of cell signaling pathways, such as the TGF-β pathway.

The N-terminal cytoplasmic domain of TBC1D29P is rich in various conserved proteins, including the heat shock protein (Hsp) domain, the K-type ATPase (KATP) domain, and the 尾-sheet protein (尾SP) domain. These domains are involved in various cellular processes, including stress response, energy metabolism, and cell signaling.

Expression and Localization

TBC1D29P is expressed in various tissues and cells, including human cancer cells, where it is involved in the regulation of cell growth, apoptosis, and angiogenesis. The expression level of TBC1D29P varies depending on the specific cell type and the environment, but it is generally high in cancer cells and low in normal tissues.

TBC1D29P is predominantly localized to the cytoplasm of cells, where it is involved in the regulation of various cellular processes, including cell adhesion, migration, and invasion. The cytoplasmic domain of TBC1D29P is well conserved and is involved in the formation of a complex with other cytoplasmic proteins, including the 尾SP protein.

Drug Sensitivity and Toxicity

TBC1D29P is a drug-sensitive protein and can be targeted by various small molecules, including inhibitors of the TGF-β pathway. In cell culture experiments, TBC1D29P has been shown to be sensitive to inhibitors of the TGF-β pathway, including inhibitors of the FAK kinase (FAK) and the Src tyrosine kinase.

TBC1D29P is also a potential biomarker for various diseases, including cancer. The expression of TBC1D29P has been shown to be elevated in various types of cancer, including breast, lung, and colorectal cancer. Therefore, targeting TBC1D29P with small molecules or antibodies could be a promising approach for the development of new therapeutic approaches for various types of cancer.

Conclusion

TBC1D29P is a putative drug target and biomarker that has the potential to modulate various cellular processes in the development and progression of diseases. The unique N-terminal transmembrane domain and cytoplasmic domain of TBC1D29P make it an attractive target for small molecules and antibodies. Further studies are needed to fully understand the function of TBC1D29P and its potential as a drug target

Protein Name: TBC1 Domain Family Member 29, Pseudogene

The "TBC1D29P Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about TBC1D29P comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets